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Annual mammographic screening to reduce breast cancer
mortality in women from age 40 years: long-term follow-up of
the UK Age RCT
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Background: There remains disagreement on the long-term effect of mammographic screening in
women aged 40–49 years.
Objectives: The long-term follow-up of a randomised controlled trial that offered annual mammography
to women aged 40–49 years. The estimation of the effect of these mammograms on breast cancer and
other-cause mortality, and the effect on incidence, with implications for overdiagnosis.
Design: An individually randomised controlled trial comparing offering annual mammography with
offering usual care in those aged 40–48 years, and thus evaluating the effect of annual screening entirely
taking place before the age of 50 years. There was follow-up for an average of 23 years for breast cancer
incidence, breast cancer death and death from other causes. We analysed the mortality and incidence
data by Poisson regression and estimated overdiagnosis formally using Markov process models.
Setting: Twenty-three screening units in England, Wales and Scotland within the NHS Breast
Screening Programme.
Participants: Women aged 39–41 years were recruited between 1990 and 1997. After exclusions, a
total of 53,883 women were randomised to undergo screening (the intervention group) and 106,953
women were randomised to have usual care (the control group).
Interventions: The intervention group was invited to an annual breast screen with film mammography,
two view at first screen and single view thereafter, up to and including the calendar year of their
48th birthday. The control group received no intervention. Both groups were invited to the National
Programme from the age of 50 years, when screening is offered to all women in the UK.
Main outcome measures: The main outcome measures were mortality from breast cancers diagnosed
during the intervention phase of the trial (i.e. before the first National Programme screen at 50 years),
mortality from all breast cancers diagnosed after randomisation, all-cause mortality, mortality from
causes other than breast cancer, and the incidence of breast cancer.
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Results: There was a statistically significant 25% reduction in mortality from breast cancers diagnosed
during the intervention phase at 10 years’ follow-up (relative rate 0.75, 95% confidence interval 0.58
to 0.97; p = 0.03). No reduction was observed thereafter (relative rate 0.98, 95% confidence interval
0.79 to 1.22). Overall, there was a statistically non-significant 12% reduction (relative rate 0.88, 95%
confidence interval 0.74 to 1.03; p = 0.1). The absolute benefit remained approximately constant over
time, at one death prevented per 1000 women screened. There was no effect of intervention on other-
cause mortality (relative rate 1.02, 95% confidence interval 0.97 to 1.07; p = 0.4). The intervention
group had a higher incidence of breast cancer than the control group during the intervention phase
of the trial, but incidence equalised immediately on the first National Programme screen at the age of
50–52 years.
Limitations: There was 31% average non-compliance with screening and three centres had to cease
screening for resource and capacity reasons.
Conclusions: Annual mammographic screening at the age of 40–49 years resulted in a relative
reduction in mortality, which was attenuated after 10 years. It is likely that digital mammography
with two views at all screens, as practised now, could improve this further. There was no evidence
of overdiagnosis in addition to that which already results from the National Programme carried out
at later ages.
Future work: There is a need for research on the effects of modern mammographic protocols and
additional imaging in this age group.
Trial registration: Current Controlled Trials ISRCTN24647151.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 24,
No. 55. See the NIHR Journals Library website for further project information. Other funding in the past
has been received from the Medical Research Council, Cancer Research UK, the Department of Health
and Social Care, the US National Cancer Institute and the American Cancer Society.
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Plain English summary
It is known that breast cancer screening with mammography (i.e. X-ray of the breasts) in womenaged ≥ 50 years leads to a reduction in the number of deaths from breast cancer. In the UK, the
NHS Breast Screening Programme offers regular screening to women aged 50–70 years. There is still
some disagreement about the effect of such screening on the risk of death from breast cancer for
those aged 40–49 years. There is also concern about overdiagnosis, that is, the finding of breast
cancer that would not have been diagnosed in a woman’s lifetime if she had not been screened.
This study recruited 160,921 women aged 39–41 years and randomly assigned one in three of the
women to be offered annual mammographic screening from age 40 to 48 years. The women were
followed up for occurrence of breast cancer, death from breast cancer and death from all other causes.
We found that the women who were offered the screening were 25% less likely to die of breast cancer
in the first 10 years in the trial. This mortality reduction was reduced with later follow-up, with a
12% reduction after an average of 23 years. There was no effect of offering screening on death from
other causes.
During the early years of the trial, the women offered screening had larger numbers of breast cancers
diagnosed, but this excess disappeared after the first National Programme screen. This suggests that
there is no overdiagnosis from screening those aged 40–49 years over and above that which already
results from screening those aged ≥ 50 years.
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Scientific summary
Background
The effect of mammographic screening on breast cancer mortality in women aged < 50 years has been
a matter for discussion for several decades. A lesser effect of screening on breast cancer mortality
has been observed for women aged < 50 years in randomised controlled trials, partly because this
age group has more radiologically dense breast tissue than those aged ≥ 50 years, and possibly also
because of the more rapid progression of cancers diagnosed in younger women.
There is continuing disagreement and uncertainty on the magnitude of the major desirable effect of
screening in this age group, the reduction in breast cancer mortality and on some major adverse
effects, notably overdiagnosis of breast cancer. In this context, overdiagnosis is the diagnosis of breast
cancer as a result of screening that would not have occurred in the person’s lifetime if they had not
been screened.
Objectives
The primary objective was to determine the effect of annual mammographic screening on breast
cancer mortality for those aged 40–49 years. We also aimed to estimate the effect on other-cause
and all-cause mortality, and the effect on breast cancer incidence, to assess the implications for
overdiagnosis of breast cancer.
Methods
A total of 160,921 women were randomised in a 1 : 2 ratio to the intervention group or the control
group. After exclusions, the trial included 160,836 women who had data available for analysis.
Recruitment took place between October 1990 and September 1997. Individual randomisation was
performed, stratified by general practice so that one-third of the women in any practice were allocated
to the intervention group. Women were aged 39–41 years at time of entry to the trial. The trial was
conducted in 23 NHS Breast Screening Programme units in England, Wales and Scotland. Women in
the intervention group were sent a letter of invitation and an information leaflet that clearly stated
that the woman was being asked to participate in a research trial, and that her acceptance of the
invitation was taken to be her informed consent to participate. Women in the intervention group were
invited for annual mammography screening until the calendar year of their 48th birthday. At 50 years,
both they and the women in the control group became eligible for 3-yearly invitation to screening as
part of the NHS Breast Screening Programme, and received their first invitation between the ages of
50 and 52 years.
Screening in the trial was by two-view mammography at the first screen, with single-view mammography
thereafter unless otherwise indicated. Mammograms were double-read. All women, including non-
attenders, were reinvited annually unless they requested otherwise. Women who moved to areas that
were not covered by the trial were not reinvited for screening as part of the trial, but were able to
self-refer to either their previous or their nearest participating screening centre. Screening in three
centres ceased prematurely (after four, five and six rounds) because of the inability of the centres to
manage the additional workload with the available resources.
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Women were flagged for follow-up by the NHS Central Register (a responsibility now belonging to the
Office for National Statistics with data collation by NHS Digital), and the triallists were notified of all
breast cancers, breast cancer deaths and deaths from all other causes up to 28 February 2017.
Mortality data from breast cancers, other causes and all causes were analysed by Poisson regression
for significance testing between the intervention and the control groups, and for the estimation of
relative rates and confidence intervals on these. In addition, we calculated Nelson–Aalen estimates of
cumulative hazard.
The primary end point was mortality from breast cancers diagnosed in the intervention phase of the trial,
before the first National Programme invitation. In estimating the effect on mortality from cancers diagnosed
in the intervention period of the trial, there is a potential bias against the intervention because the
intervention group will include deaths from cancers diagnosed at screening whose time of diagnosis would
have been at or after the first NHS Programme invitation, and which would therefore not be included in the
control group. This bias can be minimised by including cancers diagnosed at a contemporaneous screen at
the end of the intervention period in both groups.We therefore performed a secondary analysis redefining
the intervention period cancers as those diagnosed up to and including the first NHS Programme screen in
both groups.
We compared incidence between the intervention and control groups before the first National Programme
screen, up to and including the first National Programme screen and up to the final follow-up at
28 February 2017.We also derived tentative estimates of overdiagnosis using Markov process models.
Results
At 10 years, there was a statistically significant 25% reduction in mortality (relative rate 0.75, 95%
confidence interval 0.58 to 0.97; p = 0.03). For ≥ 10 years, there was no reduction observed (relative
rate 0.98, 95% confidence interval 0.79 to 1.22; p = 0.9). Overall, there was a 12% reduction in breast
cancer mortality, which was not statistically significant (relative rate 0.88, 95% confidence interval 0.74
to 1.03; p = 0.1).
For the corresponding breast cancer mortality figures for the secondary analysis of cancers diagnosed up
to and including the first NHS Programme screen in both groups, the 10-year results were identical to the
primary analysis: a statistically significant 25% reduction in mortality (relative rate 0.75, 95% confidence
interval 0.58 to 0.97; p = 0.03). For ≥ 10 years, a small, statistically non-significant reduction was observed
(relative rate 0.95, 95% confidence interval 0.77 to 1.17; p = 0.6). At complete follow-up, there was a
14% reduction in breast cancer mortality that was of borderline statistical significance (relative rate 0.86,
95% confidence interval 0.73 to 1.01; p = 0.07).
After adjustment for selection bias, the effect of actually being screened was estimated as a
statistically significant 34% reduction in breast cancer mortality up to 10 years after randomisation
(relative rate 0.66, 95% confidence interval 0.46 to 0.95; p = 0.02), a statistically non-significant 2%
reduction after 10 years (relative rate 0.98, 95% confidence interval 0.75 to 1.27; p = 0.9) and a
statistically non-significant 16% reduction overall (relative rate 0.84, 95% confidence interval 0.68 to
1.04; p = 0.1).
There was no difference between intervention and control groups in mortality from other causes than
breast cancer (relative rate 1.02, 95% confidence interval 0.97 to 1.07; p = 0.4) or from all-cause
mortality (relative rate 1.01, 95% confidence interval 0.96 to 1.05; p = 0.8).
There was an excess of cancers (total invasive and in situ) up to the time of the first National
Programme screen, which was not present thereafter. Tentative formal estimation of overdiagnosis
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suggested that 80 breast cancers were overdiagnosed in the intervention phase of the trial, 8.5% of
cancers diagnosed in this period in the intervention group, and an absolute rate of 0.2% over eight
annual screens. However, the equalisation of incidence at the time of the first National Programme
screen indicates that these would have been diagnosed by screening after the age of 50 years in any case.
Conclusions
Annual mammographic screening at 40–49 years conferred a reduction in breast cancer mortality.
The relative reduction is attenuated after 10 years, possibly because of a lesser effect of screening in
some aggressive grade 3 tumours in this age group. There was no evidence of overdiagnosis in addition
to that which already results from the National Programme carried out at later ages. These results
pertain to the epoch before digital mammography and universal two-view imaging, so the effectiveness
nowadays may be greater than that observed here.
Trial registration
This trial is registered as ISRCTN24647151.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 55.
See the NIHR Journals Library website for further project information. Other funding in the past has
been received from the Medical Research Council, Cancer Research UK, the Department of Health and
Social Care, the US National Cancer Institute and the American Cancer Society.
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Chapter 1 Introduction
In the UK, as in many other countries, following unequivocal evidence from randomised controlled trials(RCTs),1 breast cancer screening with X-ray mammography is offered to women aged 50–70 years.2
The interscreening interval is 3 years. The effect of mammographic screening on breast cancer mortality
in women aged < 50 years has been a matter for discussion for several decades.3–6 A lesser effect of
screening on breast cancer mortality has been observed for women aged < 50 years in the RCTs, partly
because this age group has more radiologically dense breast tissue than those aged ≥ 50 years, and
possibly also because of the more rapid progression of cancers diagnosed in younger women.7 We do
not propose to report on a full systematic review of the evidence here. However, to put this report in
context, we provide a brief narrative overview of the major international reviews, evidence summaries
and consequent recommendations in recent years regarding the age at which to start breast screening.
What follows is not an exhaustive list of organisations making recommendations on breast cancer
screening for this age group, but it is representative and demonstrates the variation in conclusions from
major reviews of the subject.
Following an independent systematic review, the American Cancer Society made a strong recommendation
for screening commencing at the age of 45 years and a qualified recommendation that women aged
40–44 years have the opportunity to start screening at any point during ages 40–44 years.8 The US
Preventive Services Task Force (USPSTF) recommends screening from the age of 50 years and notes that
screening between the ages of 40 and 49 years is a matter of individual choice.9 The American College of
Radiology, on the other hand, recommends annual mammographic screening from the age of 40 years.10
The International Agency for Research on Cancer concluded that there was limited evidence that
mammographic screening reduced mortality from breast cancer in women aged 40–49 years.11 The
European Guidelines for Breast Cancer Screening and Diagnosis include a conditional recommendation
for screening at ages 45–49 years, but not at ages 40–44 years.12
In 2007, the UK’s Cancer Reform Strategy announced a policy to extend breast screening to nine
screening rounds between the ages of 47 and 73 years, presumably because of considerations of
similarity between the ages of 47–49 years and 50 years with respect to screening effects and breast
cancer.13 However, this policy was never fully implemented and remains under research.
Although recommendations vary with respect to mammographic screening in women aged < 50 years,
there is a general conclusion, with few dissenters, for example Miller,4 that screening in this age group
does prevent deaths from breast cancer. However, the absolute magnitude of the estimated mortality
benefit varies substantially between reviews. The American Cancer Society’s review, published in 2015,
estimates that between 753 and 1770 persons will need to be screened in the age group 40–49 years
to prevent one breast cancer death.8 In 2016, the USPSTF quotes a figure of 3333 persons needing to
screen in the age group 39–49 years to prevent one breast cancer death.14 The European Guidelines,
published online in 2019, quote that between 1299 and 2273 people aged between 45 and 49 years
need to be screened to prevent one breast cancer death.12 The differences in estimates of absolute
benefit are because of the variation in a number of inputs, principally the follow-up period for cancer
deaths (because screening in the present prevents deaths 10, 15 or 20 years in the future) and the
relative risk estimate used.
In view of the continuing uncertainties and variability of estimates of benefit, it is important to exploit
to the full all UK research resources that address this issue. In the UK, there are two RCTs specifically
aimed at this age group: the UK Breast Screening Age trial (comparing usual care with annual screening for
7 years from age 39 to 41 years, with follow-up continuing thereafter)15 and the ongoing Age Extension
(AgeX) trial [evaluating extending the age range of the NHS Breast Screening Programme (NHSBSP)
from 50–70 to 47–73 years].16 The AgeX trial is essentially two trials, one offering screening at ages
47–49 years and another offering screening at ages 71–73 years.
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The UK Breast Screening Age trial was initiated in 1990 and now has an average of > 23 years’
follow-up. After exclusions, this trial randomised 106,953 women aged 39–41 years to the usual care
group and 53,883 women to the intervention group (i.e. they were offered annual mammography for
7 years). The 17-year results were published in 2015 and showed a 25% reduction in breast cancer
mortality with screening at 10 years, although this was attenuated with further follow-up.17 We now
have follow-up data to an average of 23 years. The follow-up phase is a National Institute for Health
Research (NIHR) Health Technology Assessment (HTA) programme-funded project and is the subject
of this report.
The aims of the follow-up project as set out in the protocol were:
l Analysis comparing breast cancer, other cause and all-cause mortality between intervention and
control groups to the end of 2010.
l The same analysis to the end of 2017. The primary end point will be mortality from breast cancers
diagnosed during the intervention phase of the trial, when the intervention group was invited to
screening and the control group was not, that is, for all women in intervention and control groups,
up to immediately before their first NHSBSP invitation.
l Analyses of cumulative mortality from breast cancer over the total follow-up period and at 5, 10
and 15 years from randomisation.
l Analysis of cumulative mortality from breast cancers diagnosed before first National Programme
screen, for the most part diagnosed at ages 40–49 years.
l Estimation of the effect of screening in those women attending for screening (‘per-protocol’
analysis). This will use an established method18 to adjust for selection bias, which arises because
non-attenders for screening are likely to be at different level of risk of breast cancer mortality than
those attending.
l Estimation of the absolute long-term benefit of screening in terms of the number needed to screen
in this age group to prevent one breast cancer death.
l Analyses of the cumulative incidence of breast cancer, invasive and in situ, by trial from date
of trial entry will be conducted. We will look specifically at incidence prior to the first NHSBSP
invitation, incidence up to and including the first NHS National Programme screen-detected
cancers and incidence up to the end of follow-up. We shall estimate overdiagnosis overall, and
the additional overdiagnosis from starting screening at 40 years instead of 50 years, as in the
National Programme.
The first aim has already been achieved and published, with results reported to 2011.17 For completeness,
the results will be briefly summarised in this report. In addition to the analyses above, we shall estimate
overdiagnosis with formal adjustment for lead time, that is, separating excess incidence because of earlier
diagnosis from excess incidence because of overdiagnosis.19 We shall also conduct ‘diagnostic’ analysis to
clarify the reasons for specific results, such as the early mortality benefit that is later diluted.17
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Chapter 2 Methods
Trial design
The trial profile is summarised in Figure 1. A total of 160,921 women were randomised in a 1 : 2 ratio
to the intervention or the control group, and after exclusions the trial included 160,836 women who
had data available for analysis. Recruitment took place between October 1990 and September 1997.
Individual randomisation was performed and stratified by general practice so that one-third of the
women in any practice were allocated to the intervention group. Women were identified from general
practitioner (GP) lists then held by Family Heath Services Authorities. Randomisation was at the
individual level, stratified by general practice. GPs were given prior sight of lists and could remove
women whom they considered unsuitable for invitation, for example those already under care for
breast cancer from 1992 onwards, randomisation and allocation to a trial group were carried out on
the health authorities’ computer system using ad hoc software. Prior to this, in three centres that
started the trial early, random numbers generated by the trial co-ordinator were applied to GP lists
from the Family Health Services Authorities. It was not possible to blind the screening centres to trial
group allocation.
Women were aged 39–41 years at time of entry to the trial. The trial was conducted in 23 NHSBSP
screening units in England,Wales and Scotland. Participating units are listed in the appendix to Moss et al.17
Women in the intervention group were sent a letter of invitation and information leaflet that clearly stated
that the woman was being asked to participate in a research trial, and her acceptance of the invitation was
Women
aged 40–41 years
randomised
(n = 160,921)
Intervention group
(n = 53,914)
Invited to annual screening 
to age 48 years
Control group
(n = 107,007)
Usual care
Excluded from analysis
• Not traced at ONS/NHSD, n = 8
• Died before entry, n = 19
• Emigrated before entry, n = 15
• Male, n = 12
Excluded from analysis
• Not traced at ONS/NHSD, n = 8
• Died before entry, n = 10
• Emigrated before entry, n = 7
• Male, n = 6
n = 53,883 n = 106,953
Invited for screening in
NHSBSP from age 50 years
Invited for screening in
NHSBSP from age 50 years
FIGURE 1 Flow diagram of trial profile. NHSD, NHS Digital; ONS, Office for National Statistics.
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taken to be her informed consent to participate.Women in the intervention group were invited to eight
annual mammographic screens, until the calendar year of their 48th birthday. Thus, the trial was designed
to evaluate screening, all of which took place before the age of 50 years. At 50 years, both they and the
women in the control group became eligible for 3-yearly invitation to screening as part of the NHSBSP,
and received their first invitation between the ages of 50 and 52 years.
Screening in the trial was by two-view mammography at the first screen, with single-view mammography
thereafter unless otherwise indicated. Mammograms were double-read. All women, including non-
attenders, were reinvited annually unless they requested otherwise. Women who moved to areas that
were not covered by the trial were not reinvited for screening as part of the trial, but were able to
self-refer to either their previous or their nearest participating screening centre. Screening in three
centres ceased prematurely (after four, five and six rounds) because of the inability of the centres to
manage the additional workload with the available resources.
The trial database contains information on all screening as part of the trial in women in the intervention
group. It also contains data on the first screening invitation and attendance at ages 50–52 years as
part of the NHSBSP in women in both the intervention and the control groups. These data on the first
screening invitation and attendance at ages 50–52 years have been collected not only from the 23 centres
participating in the trial but also from all NHSBSP screening units in England,Wales and Scotland, thus
providing information on screening in women who have moved away from their original trial centre.
Data on this first NHSBSP screen were estimated to be 93% complete, with similar percentages in the
two trial groups. Information on screening includes attendance, outcome of initial mammogram (i.e. whether
or not the woman was recalled for further assessment) and final outcome of the screening episode.
Up to the end of 2009, pathological information including in situ/invasive status, invasive tumour size,
lymph node status and histological grade was routinely supplied to the triallists. In addition, prior to 2009,
pathology was reviewed and the pathological variables reclassified by a panel of three expert breast
pathologists, using pathology slides where available.20,21 Of the 7890 breast cancers diagnosed between
the start of the trial and February 2017, 3641 (46%) underwent full pathological review. This included all
cancers diagnosed in the intervention phase of the trial. In cases undergoing review, there was good
agreement between original and reviewed classifications with respect to invasive status, tumour size,
histological grade and node status.20 In the analyses below, reviewed pathology classifications were used
where available; otherwise, classifications from the original pathology reports were used.
The primary outcome measure of the trial is mortality from breast cancer. As noted above, the primary
end point was mortality from breast cancers diagnosed during the intervention phase of the trial, when
the intervention group was invited to screening and the control group was not (i.e. before the first
NHSBSP invitation, from which point both groups were invited to screening). It was decided from the
outset of the trial to use underlying cause of death from the death certificate rather than undertake a
verification exercise. All women in this trial were flagged at the NHS Central Register, now controlled
by NHS Digital, and > 99.9% were successfully traced. This register provides data on all cancer
registrations and deaths, including data on underlying coded cause of death. We have notifications to
28 February 2017, an average follow-up of 23 years. We had originally planned to have data to the
end of 2017 but because of changes in information governance policies on the part of the data
custodians, notifications ceased 10 months early.
Statistical methods
The trial was originally designed to recruit 190,000 women to have 80% power for a 20% reduction
in breast cancer mortality at 10 years’ follow-up, at 5% significance level. However, financial and
workload constraints on NHS breast screening units slowed recruitment and no new centres entered
after 1996. In 1999, the Data Monitoring Committee recommended that, as further accrual would
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result in only marginal gains in power and would delay achievement of mean follow-up times,
recruitment should cease.15 The revised power, based on the original estimates of breast cancer
mortality in the control group of 3.3 per 1000, was 72% at 10 years’ follow-up and 80% at 14 years’
follow-up. See the protocol of this follow-up project.22 Mortality data over time were analysed by
Poisson regression for the purpose of significance testing between the intervention and the control
groups, and for the estimation of relative rates (RRs) and confidence intervals (CIs) on these. This is
the recommended method of analysis for data on counts of events in a given period.23 In addition,
we calculated Nelson–Aalen estimates of cumulative hazard.24 For the primary end point, in addition to
estimating the intention-to-treat effect, we also estimated the effect of actually being screened using
the method described in Cuzick et al.18
In estimating the effect on mortality from cancers diagnosed in the intervention period of the trial,
there is a potential bias against the intervention because the intervention group will include deaths
from cancers diagnosed at screening whose time of diagnosis would have been at or after first NHS
Programme invitation, and which would therefore not be included in the control group. Duffy and
Smith25 describe how the bias can be minimised by including cancers diagnosed at a contemporaneous
screen at the end of the intervention period in both groups. Therefore, we performed a secondary
analysis redefining the intervention period cancers as those diagnosed up to and including the first
NHS Programme screen in both groups.
In addition to mortality from breast cancer, we also estimated the effect of intervention on deaths
from all causes and deaths from causes other than breast cancer. In particular, we considered deaths
from causes other than breast cancer in the breast cancer patients. If there was any systematic bias
in classification of death from breast cancer with respect to screening status, we would expect to see
different rates of death from other causes in the breast cancer patients between the intervention and
the control group.
We estimated incidence of breast cancer, in situ and invasive, in the intervention and the control
groups, up to just before first NHSBSP screen, up to and including first NHSBSP screen and up to end
of follow-up (i.e. February 2017). For estimation of overdiagnosis, we used the customary definition of
breast cancers diagnosed as a result of screening that would not have been diagnosed in the person’s
lifetime if screening had not taken place. Formal estimation of overdiagnosis therefore implies quantitative
estimates of the size of this subgroup of cancers and is not simply a comparison of incidence between
screened and unscreened groups, which is affected by lead time. However, such estimation is tentative
(i.e. it has associated uncertainties in addition to simple statistical variation) because, for a given cancer
that is detected by screening and treated, we can never know what would have happened if it had not
been diagnosed and treated at that point. We derived estimates of overdiagnosis by estimating the
expected numbers of cancers detected at each screen if there were no overdiagnosis, and subtracting
these from the observed numbers. The expected numbers were derived as a function of estimates of
screening test sensitivity and mean sojourn time (the duration of the preclinical screen-detectable
period); the latter was estimated by maximum likelihood from interval cancer rates, which, by definition,
do not include overdiagnosed cancers.26
To estimate the expected number of cancers at incident (second and subsequent) screens, we used the
estimate of programme sensitivity (the proportion of cancers detected at screening in a population
attending screening). This was derived by Launoy et al.27 as:
Ps =
s(1−e−λt)
λt(1− (1−s)e−λt)
: (1)
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The expected number of screen-detected cancers at a given screen E should satisfy:
Ps =
E
E + C
, (2)
where C is the number of interval cancers corresponding to that screening round. Thus, we calculate
E as:
E =
PsC
1−Ps
. (3)
We derived independent estimates of S for individual screens at 40–47 years by interpolation and
extrapolation of the estimates of Carney et al.,28 who calculated sensitivity as 68.6% at 40–44 years
and 72.5% at 45–49 years. We estimated λ conditional on these sensitivity estimates from the incidence
of interval cancers, modelling progression from preclinical cancer to clinical symptomatic disease as a
Markov process. Further details are given by Michalopoulos and Duffy.26
This method cannot be used for first screens. However, the expected number of cancers diagnosed at a
prevalent (first) screen is:
NpIS
λ
, (4)
where S and λ are as defined above, Np is the number of women screened for the first time and I is the
underlying incidence. We estimated the underlying incidence among screening attenders as 0.573 per
1000 per year, by adjusting the control group incidence for selection bias (those who choose to be
screened have potentially different risk of breast cancer from those who do not) using the method
described in Moss et al.29
METHODS
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Chapter 3 Mortality results
Reporting policy
The results are reported in line with Consolidated Standards of Reporting Trials (CONSORT) guidelines.
Recap on 2011 results
At the time of analysis of the 2011 mortality results, we had a median follow-up time of 17 years.
Table 1 shows the cumulative person-years, breast cancer deaths (from cancers diagnosed up to the
end of the intervention period, as noted in Chapter 2) and RRs with 95% CIs on these, for deaths prior
to 10 years from randomisation, deaths occurring ≥ 10 years after randomisation and all deaths from
these breast cancers. Average ages during the two periods (i.e. prior to 10 years and ≥ 10 years) were
45 and 54 years, respectively. There was a statistically significant reduction in mortality in the first
10 years (RR 0.75, 95% CI 0.58 to 0.97), but no reduction thereafter (RR 1.02, 95% CI 0.80 to 1.30).
Table 2 shows cumulative deaths from all breast cancers diagnosed since randomisation by trial group
and 5-year period, not only those diagnosed during the intervention period as in Table 1. Thus, even in
the first 10 years, numbers are slightly larger than those in Table 1. Note that these are cumulative
rather than period specific as in Moss et al.17 Again, there was an early reduction in mortality that was
later diluted. It should be noted that the later period in Table 2 includes deaths from cancers diagnosed
after both groups of the trial were subject to screening in the National Programme, so dilution is expected.
TABLE 1 Mortality from breast cancers diagnosed in the intervention period, by trial group and period of observation,
to 31 December 2011
Period of observation (years)
Intervention group Control RR
RR (95% CI)Deaths Person-years Deaths Person-years
0 to < 10 83 532,747 219 1,058,322 0.75 (0.58 to 0.97)
≥ 10 99 408,221 193 810,395 1.02 (0.80 to 1.30)
Total 182 940,968 412 1,868,717 0.88 (0.74 to 1.04)
TABLE 2 Cumulative mortality from all breast cancers diagnosed since randomisation to 31 December 2011
Period of observation (years)
Intervention group Control group
RR (95% CI)Deaths Person-years Deaths Person-years
0 to < 5 27 267,864 69 532,104 0.78 (0.50 to 1.21)
0 to < 10 83 532,748 221 1,058,324 0.75 (0.58 to 0.97)
0 to < 15 181 793,911 406 1,576,547 0.89 (0.74 to 1.07)
Total 242 940,969 515 1,876,717 0.93 (0.80 to 1.09)
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At follow-up to the end of 2011, there were 2127 deaths from all causes in the intervention group
(940,969 person-years), and 4320 in the control group (1,868,717 person-years). This gave a RR of
0.98 (95% CI 0.93 to 1.03).
When interpreting the 2011 results, it was noted that both short- and long-term survival in the
intervention group were improved for those with cancers of histological grades 1 and 2, but that
improved survival was observed only in the first 10 years for those with grade 3 cancers.17 This
suggested that, for these more aggressive tumours, early detection was delaying but not preventing
death from breast cancer. This would go some way to explaining the attenuation of the mortality
benefit after 10 years.
Breast cancer mortality to February 2017
Table 3 shows breast cancer mortality to February 2017 from the cancers diagnosed during the
intervention phase of the trial, up to 10 years after randomisation and from 10 years onwards, by group.
The corresponding Nelson–Aalen cumulative mortality graphs are given in Figure 2. At 10 years there was a
statistically significant 25% reduction in mortality (RR 0.75, 95% CI 0.58 to 0.97; p = 0.03). For ≥ 10 years,
no reduction was observed (RR 0.98, 95% CI 0.79 to 1.22; p = 0.9). Overall, there was a 12% reduction in
breast cancer mortality, which was not statistically significant (RR 0.88, 95% CI 0.74 to 1.03; p = 0.1).
The absolute benefit, however, remains similar regardless of follow-up period (see Figure 2).
TABLE 3 Mortality from breast cancers diagnosed in the intervention period, by trial group and period of observation,
Period of observation (years)
Intervention group Control group
RR (95% CI)Deaths Person-years Deaths Person-years
0 to < 10 83 532,729 219 1,058,236 0.75 (0.58 to 0.97)
≥ 10 126 668,281 255 1,326,770 0.98 (0.79 to 1.22)
Total 209 1,201,010 474 2,385,006 0.88 (0.74 to 1.03)
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FIGURE 2 Cumulative breast cancer mortality to February 2017 from cancers diagnosed during the intervention phase
of the trial.
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to 28 February 2017
There were 55 deaths in non-attenders, lapsed attenders or those who had ceased screening, 32 deaths
before 10 years after randomisation and 23 thereafter. This gives the selection bias-adjusted per-protocol
effect of being screened as a statistically significant 34% reduction in breast cancer mortality up to
10 years after randomisation (RR 0.66, 95% CI 0.46 to 0.95; p = 0.02), a statistically non-significant
2% reduction after 10 years (RR 0.98, 95% CI 0.75 to 1.27; p = 0.9) and a statistically non-significant
16% reduction overall (RR 0.84, 95% CI 0.68 to 1.04; p = 0.1).18
Table 4 shows the corresponding breast cancer mortality figures for the secondary analysis of cancers
diagnosed up to and including the first NHS Programme screen in both groups. Numbers are larger
than in Table 3 because of the additional inclusion of cancers diagnosed at the first NHS Programme
screen. At 10 years, the results were identical to the primary analysis: a statistically significant 25%
reduction in mortality (RR 0.75, 95% CI 0.58 to 0.97; p = 0.03). For ≥ 10 years, a small, statistically
non-significant, reduction was observed (RR 0.95, 95% CI 0.77 to 1.17; p = 0.6). Overall, there was a
14% reduction in breast cancer mortality, which was of borderline statistical significance (RR 0.86, 95% CI
0.73 to 1.01; p = 0.07). There was no statistically significant effect of the intervention on mortality from
breast cancers diagnosed after the intervention period (RR 0.99, 95% CI 0.79 to 1.24; p= 0.9).
Table 5 shows cumulative deaths from all breast cancers diagnosed since randomisation by trial group
and 5-year period, up to 28 February 2017. The corresponding Nelson–Aalen plots of cumulative
mortality by continuous time are shown in Figure 3. Again, there was an early reduction in mortality
that was later diluted, as expected.
The absolute reduction in breast cancer mortality was 0.6 per 1000 women invited. This corresponds
to needing to invite 1667 women and, given the 65% average participation rate, needing to screen
1083 women in this age group to prevent one breast cancer death. This finding is relatively stable over
time and end point. At 10 years, the number of women who would need to be screened is 1300. At the
final follow-up, using only deaths from cancers diagnosed during the intervention phase, the figure is
1300, and for the secondary end point including the cancers diagnosed at first NHSBSP screen the
number needed to screen is 1050.
TABLE 4 Mortality from breast cancers diagnosed up to and including the first NHSBSP screen, by trial group and period
of observation, to 28 February 2017
Period of observation (years)
Intervention group Control group
RR (95% CI)Deaths Person-years Deaths Person-years
0 to < 10 83 532,729 219 1,058,236 0.75 (0.58 to 0.97)
≥ 10 133 668,281 279 1,326,770 0.95 (0.77 to 1.17)
Total 216 1,201,010 498 2,385,006 0.86 (0.73 to 1.01)
TABLE 5 Cumulative mortality from all breast cancers diagnosed since randomisation to 28 February 2017
Period of observation (years)
Intervention group Control group
RR (95% CI)Deaths Person-years Deaths Person-years
0 to < 5 27 267,852 69 532,066 0.78 (0.50 to 1.21)
0 to < 10 83 532,729 221 1,058,236 0.75 (0.58 to 0.96)
0 to < 15 182 793,852 406 1,576,346 0.89 (0.75 to 1.06)
Total 338 1,201,010 743 2,385,006 0.90 (0.79 to 1.03)
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All-cause and other-cause mortality
Figure 4 shows the Nelson–Aalen cumulative mortality from all causes over time. There was no
difference in all-cause mortality to the end of follow-up between the two groups (RR 1.01, 95% CI
0.96 to 1.05; p = 0.8). For mortality from causes other than breast cancer, the result was very similar
(RR 1.02, 95% CI 0.97 to 1.07; p = 0.4).
We also investigated two further specific causes of death, all cancers (including breast cancer) and
ischaemic heart disease. There was no statistically significant effect on deaths from all cancers
(RR 0.98, 95% CI 0.93 to 1.05; p = 0.6). Similarly, no statistically significant effect was observed on
deaths from ischaemic heart disease (RR 1.03, 95% CI 0.87 to 1.20; p = 0.7).
In considering deaths from all causes and causes other than breast cancer, it is worth investigating the
deaths of the cancer patients, in case treatment of cancers has a differential effect on mortality between
the study and control groups. Accordingly, we compared the intervention and control groups with
respect to fatality from all causes and all causes except breast cancer in the breast cancer patients.
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FIGURE 3 Cumulative breast cancer mortality, regardless of time of diagnosis, from randomisation to 28 February 2017.
0
0
20
10
A
ll-
ca
u
se
 m
o
rt
al
it
y 
ra
te
 p
er
 
1
0
0
0
 p
er
so
n
-y
ea
rs
40
30
60
50
70
5 10 15 20 25
Years in trial
Control group
Intervention group
FIGURE 4 Cumulative mortality from all causes from randomisation to 28 February 2017.
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The results showed a statistically significant reduction in fatality from any cause in breast cancer patients
in the intervention group (RR 0.87, 95% CI 0.77 to 0.98; p = 0.02) and a statistically non-significant
reduction in the number of deaths from causes other than breast cancer in the intervention group
(RR 0.86, 95% CI 0.67 to 1.11; p = 0.2). This suggests that there is no bias in favour of screening from
using death from breast cancer as the end point.
Further investigation of the reduction in effect over time
As noted above, it was suggested in the report on the 2011 results that one possible reason for the
reduction in the effect on breast cancer mortality, even using only those cancers diagnosed in the
intervention period, may have been a reduced effect of early detection on invasive cancers of
histological grade 3. The suggestion was that, for these more aggressive tumours, the early detection
may have, on average, only postponed death from breast cancer rather than preventing it altogether.
Although the relatively stable absolute effect suggests that the theory of postponement rather than
prevention of death is not the issue, results from this further follow-up are consistent with a lesser
effect of screening on grade 3 cancers. Figure 5 shows survival by group for invasive tumours of grades
1 and 2 combined (this shows survival from randomisation rather than diagnosis to avoid issues of lead
time bias). There is a survival advantage for the intervention group, which persists over the long term.
Figure 6 shows the corresponding survival curves for invasive grade 3 cancers. Note that rather larger
numbers in the intervention group had usable pathology data as more of these were diagnosed in the
intervention period when supply of pathology data to the triallists was routine.
Population mortality results, which avoid potential biases from length bias and overdiagnosis, are similarly
consistent with this. Table 6 gives the mortality from breast cancer by grade and group for 5, 10, 15 and
20 years of follow-up. For tumours of grades 1 and 2, there is an approximate 30% reduction in mortality
that is maintained at long-term follow-up. For grade 3 cancers, there is a lesser mortality reduction that is
no longer present by 15 years of follow-up.
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FIGURE 5 Survival to death from breast cancer of invasive cancers of grades 1 or 2, diagnosed during the intervention
period by trial group.
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TABLE 6 Cumulative breast cancer mortality by grade of tumour, period of follow-up and trial group
Grade
Follow-up
(years)
Intervention group Control group
RR (95% CI)
Breast cancer
deaths (n)
Rate/
1000 women
Breast cancer
deaths (n)
Rate/
1000 women
1 and 2 5 3 0.0001 9 0.0001 0.66 (0.18 to 2.44)
10 16 0.0003 47 0.0004 0.68 (0.38 to 1.19)
15 33 0.0006 93 0.0009 0.70 (0.47 to 1.05)
20 43 0.0008 112 0.0010 0.76 (0.45 to 1.08)
3 5 17 0.0003 42 0.0004 0.80 (0.46 to 1.41)
10 50 0.0009 114 0.0011 0.87 (0.62 to 1.21)
15 89 0.0017 173 0.0016 1.02 (0.79 to 1.32)
20 99 0.0018 190 0.0018 1.03 (0.81 to 1.32)
MORTALITY RESULTS
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Chapter 4 Breast cancer incidence and
estimation of overdiagnosis
Cumulative incidence of breast cancer over time
Figure 7 shows the cumulative incidence of breast cancer, invasive and in situ, from randomisation to
28 February 2017 in the intervention and control groups. Table 7 gives the number of cancers, person-
years and RRs (and 95% CIs) for incidence up to immediately before the first invitation to NHSBSP
screen, up to and including first NHSBSP screen and at complete follow-up to the end of February
2017. The RR of breast cancer incidence just before the first NHSBSP screen was 1.09 (95% CI 1.00
to 1.19; p = 0.03). The RR up to and including first NHSBSP screen was 0.99 (95% CI 0.92 to 1.07;
p = 0.7). At the end of follow-up, the RR was 0.99 (95% CI 0.94 to 1.04; p = 0.6). This indicates that
there was no excess in the intervention group in addition to cancers diagnosed in the NHSBSP from
the age of 50 years onwards. Thus, any overdiagnosis conferred by screening at 40–49 years would
occur in any case if the population were screened from ≥ 50 years.
Table 8 shows the corresponding results for invasive cancers only. The results show a very small excess
in the intervention group in the intervention phase and a very small deficit thereafter. Neither of these
differences was statistically significant.
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FIGURE 7 Cumulative incidence of breast cancer, invasive and in situ, by period of follow-up and trial group.
TABLE 7 Numbers of breast cancers, invasive and in situ, and person-years of observation, by period of follow-up and group
Period of follow-up
Intervention group Control group
RR (95% CI)
Breast
cancers Person-years
Breast
cancers Person-years
Just before first NHSBSP screen 953 569,016 1731 1,129,491 1.09 (1.00 to 1.19)
Up to and including first NHSBSP screen 1132 569,016 2278 1,129,491 0.99 (0.92 to 1.07)
Up to 28 February 2017 2617 1,174,649 5260 2,334,516 0.99 (0.94 to 1.04)
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Pathological attributes of cancers diagnosed
Owing to changes in information governance and data ownership, we do not have detailed pathology
data on more recent cancers diagnosed since the trial groups entered the National Programme.
However, from Tables 7 and 8, we can calculate that, in the intervention phase of the trial prior to the
first National Programme screen, 6% of control group cancers and 12% of intervention group cancers
were in situ. After all subjects had entered the National Programme, the corresponding figures were
close to 15% in the control group and 13% in the intervention group.
For invasive cancers diagnosed during the intervention phase, Table 9 shows the size, node status,
grade, vascular invasion status and tumour type, by trial group, giving results in the intervention group
TABLE 8 Cumulative incidence of breast cancer, invasive cancers only, by period of follow-up and trial group
Period of follow-up
Intervention group Control group
RR (95% CI)
Breast
cancers Person-years
Breast
cancers Person-years
Just before first NHSBSP screen 835 569,016 1628 1,129,491 1.02 (0.94 to 1.11)
Up to and including first NHSBSP screen 970 569,016 2021 1,129,491 0.95 (0.88 to 1.04)
Up to 28 February 2017 2288 1,177,990 4640 2,339,852 0.98 (0.93 to 1.03)
TABLE 9 Pathological factors by trial group and detection mode in the intervention group
Factor Category
Intervention group, n (%)
Control group, n (%)Screen detected Symptomatic
Total invasive 256 579 1628
Node status Negative 207 (81) 328 (61) 932 (62)
Positive 49 (19) 213 (39) 575 (38)
NK 0 38 121
Size ≤ 20 mm 196 (81) 265 (56) 788 (58)
> 20 mm 47 (19) 206 (44) 562 (42)
NK 13 108 278
Grade 1 48 (20) 50 (10) 122 (9)
2 114 (48) 184 (38) 596 (44)
3 74 (32) 253 (52) 625 (47)
NK 20 92 285
Vascular invasion Yes 53 (22) 169 (33) 439 (31)
No 189 (78) 335 (67) 989 (69)
NK 14 75 200
Tumour type Ductal 179 (72) 399 (76) 1127 (77)
Lobular 19 (8) 67 (13) 175 (12)
Medullary 3 (1) 8 (2) 17 (1)
Mucinous 4 (2) 9 (2) 32 (2)
Tubular 40 (16) 39 (7) 105 (7)
Other 1 (< 1) 2 (< 1) 15 (1)
NK 10 55 157
NK, not known.
BREAST CANCER INCIDENCE AND ESTIMATION OF OVERDIAGNOSIS
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for screen-detected and symptomatic cancers (interval cancers and cancers diagnosed in non-attenders
for screening) separately. The screen-detected cancers tended to be smaller (as expected) and were less
likely to be node positive, to be grade 3 or to have vascular invasion than the cancers in the control group
and the symptomatic cancers in the intervention group. The symptomatic cancers in the intervention group
had very similar attributes to those in the control group. There was a higher proportion of tubular
carcinoma cases in the screen-detected cancers in the intervention group, suggesting a measure of length
bias in screen detection.
Tentative estimation of overdiagnosis
Table 10 shows the numbers of screen-detected and interval cancers by screening round over the eight
screening rounds in the intervention phase of the trial, with the sensitivity estimates derived from
Carney et al.28 From the interval cancers and using maximum likelihood similarly to Michalopoulos and
Duffy,26 we estimated λ, the inverse of the mean sojourn time, as 0.92 (95% CI 0.54 to 1.49). Table 10
also shows the expected numbers of screen-detected cancers as estimated from λ and sensitivity.
The total number of expected screen-detected cancers was 164, compared with 244 observed. This
suggests that 80 cancers were overdiagnosed, 8.5% of the breast cancers diagnosed in the intervention
phase of the trial, or 32.8% of screen-detected cancers, and an absolute rate of 0.2% of women being
screened over 8 years.
In addition, the equalisation of incidence of breast cancer between the control and intervention groups
following the first NHSBSP screen indicates that these would have been diagnosed by screening after
the age of 50 years in any case. Therefore, starting screening at 40 years instead of 50 years did not
lead to any additional overdiagnosis.
TABLE 10 Women screened, observed and expected screen-detected cancers, interval cancers and sensitivity estimates,
by screening round in the intervention group
Screening
round
Women
screened (n)
Screen-detected
cancers (n)
Interval
cancers (n)
Estimated screening
sensitivity (%)
Expected
screen-detected
cancers (n)
1 35,582 31 10 67.0 15
2 33,547 21 18 68.6 19
3 31,753 23 22 69.3 23
4 31,117 22 21 70.1 22
5 31,169 34 21 70.9 23
6 29,695 34 20 71.7 22
7 28,452 37 15 72.5 17
8 24,904 42 20 73.3 23
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Chapter 5 Discussion and implications
This trial found a statistically significant 25% reduction in breast cancer mortality with the offer ofannual screening for breast cancer in the first 10 years following randomisation. The reduction was
diluted thereafter. There is some evidence that the dilution was due to a number of aggressive grade 3
cancers for which the effect of screening was small and not apparent at all after 10 years. This is in
contrast to results of the Swedish Two-County Trial on which the NHS Programme is based. In the
Two-County Trial, of women aged 40–74 years (73% were aged ≥ 50 years), most of the breast cancer
mortality reduction was in grade 3 cancers.30 The magnitude of the observed benefit is consistent
with a recent meta-analysis of the RCTs of mammography.31 However, it should be noted that our trial
specifically recruited subjects who were aged 39–41 years so that all of the trial screening would take
place before the age of 50 years. The other trials did not have this design feature.
There was no indication of an effect of the intervention on deaths from other causes, and no effect on
all-cause mortality. The latter is to be expected, as the effect on all-cause mortality is overwhelmingly
driven by causes of death on which the intervention has no effect.32 In this trial, breast cancer deaths
from cancers diagnosed in the intervention phase constituted only 7% of all deaths.
Interestingly, there was no statistically significant difference between the trial groups with respect to
ischaemic heart disease. It has been suggested that early detection implies more frequent local excision,
which in turn requires more radiotherapy, which increases the risk of ischaemic heart disease.33 This does
not seem to be the case in this trial, although the lack of an effect may be due to lack of statistical power
because there were only 17 ischaemic heart disease deaths in the breast cancer patients. It should also
be noted that, with modern techniques, risks to the heart from radiotherapy are considerably reduced.34,35
Similarly, there was no evidence of an increase in risk of death from all causes in the intervention group
or in death from other causes among breast cancer patients, suggesting that the concerns about excess
deaths from the treatment of screen-detected cancers are unfounded. It has to be admitted, however,
that there are potential inaccuracies in using cause of death as given on the death certificate. Screening
makes it more likely that a breast cancer is diagnosed and, if a subject dies with a previous diagnosis of
breast cancer, there may be a tendency for that breast cancer to be considered as either causing or
contributing to death. Some breast cancer patients may die of metastatic disease from another, occult
primary tumour and their death may then be classified as a breast cancer death.
The results translate to an absolute benefit of one breast cancer death prevented per 1000 women
regularly screened in this age group, which is considerably smaller than that observed at 50–69 years
(and requiring more frequent screening).1 However, it is a larger benefit than most of the review findings
quoted in Chapter 1, almost certainly because of the long-term follow-up reported here. In addition, it is
worth considering that technological changes that have taken place since the trial’s intervention phase
might modify this. Digital mammography rather than film is the standard, as is two-view mammography
at all screens. There is clear evidence that both substantially improve screening sensitivity, with digital
mammography specifically showing improved sensitivity in women < 50 years.36,37 It may be, however,
that the improved sensitivity of state-of-the-art screening may also result in increased overdiagnosis.
It should also be noted that therapies have changed dramatically since the inception of this trial.
We did not have access to treatment data, but, in the intervention period of this trial, the earliest diagnosis
of a breast cancer was in 1991 and the latest in 2008. It is fair to say that those cancers diagnosed
more recently in this period will have had greater access to effective and potentially tumour-targeted
systemic therapies [e.g. hormone therapies for oestrogen receptor-positive cancers, and trastuzumab
(Herceptin®; Roche Diagnostics, Hertford, UK) for human epidermal growth factor receptor 2 (HER2)-
positive cancers] than those diagnosed early in the trial period. In addition, it is not clear whether or
not the combination of modern screening and modern systemic therapies would be synergistic.
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However, it is certainly possible that earlier detection in combination with more effective treatments
may have benefits that are considerably greater than the effects observed here.
The results of analysis of breast cancer incidence rates suggest relatively low absolute levels of overdiagnosis,
and no additional overdiagnosis above that arising from screening women aged 50–70 years, as the incidence
equalised with the first NHSBSP screen at or shortly after 50 years.That is, any cancers overdiagnosed at
40–49 years in the intervention group were balanced by their equivalent cancers being overdiagnosed at
≥ 50 years in the control group. In addition, invasive cancers showed a small, statistically non-significant
deficit in the intervention group following the first NHSBSP screen. This is consistent with findings in the
NHSBSP, the Swedish Two-County Trial38 and the Gothenburg Trial39 that diagnosis and treatment of ductal
carcinoma in situ was followed by a reduction in subsequent invasive breast cancer incidence.
Overdiagnosis is not the only adverse effect of screening. Another important human cost is false-positive
recall for assessment of suspicious lesions that transpire not to be cancer. In this trial, the rate of
false positives was 4.9% at first screening and 3.2% at subsequent screens.40 The first is considerably
smaller than the corresponding first-round false-positive rate in the NHS Programme in women aged
50–70 years, and the second is comparable to the corresponding rate observed at subsequent rounds
in the NHS Programme.41 It is not clear whether or not these rates would change with more modern
screening methods.
It is planned that results reported in Chapters 3 and 4 will be expanded on and submitted separately to
peer-reviewed medical journals. In addition, further methodological work on estimation of screening
sensitivity and overdiagnosis in this population is at an advanced stage, and will be submitted in the
near future.
Limitations of the trial include the 31% average non-compliance with screening and the fact that three
centres had to cease screening for resource and capacity reasons. These would tend to bias the results
against screening. The issues are further discussed by Moss et al.17 Other limitations include the fact
that the technical aspects of the screening were considerably different from the state-of-the-art
screening today and the range of systemic treatments that are available now, which were not available
in the 1990s when much of the diagnostic and treatment activity of the trial was carried out.
What are the implications for clinical practice and future research? The results indicate that there is a
reduction in breast cancer mortality associated with the offer of screening in women aged 40–49 years.
There is no evidence of overdiagnosis in addition to that which is accrued in screening women aged
50–70 years. It is also likely that the use of digital mammography and universal two-view examination
could lead to a greater benefit. Policy-makers may usefully consider this potential improvement in addition
to the mortality benefit observed in this trial in deciding lower age limits for population screening. The
finding of a mortality reduction is likely to be generalisable from this population-based trial, but, because
of the changes in screening technology and practice, and the limitations with respect to compliance,
resource and capacity noted above, the actual size of the reduction in practice is likely to be larger than
observed here.
In terms of research, two major questions should be addressed. First, can digital mammography and
universal double-reading improve on the effects observed here, in particular the long-term effects?
In this respect, an update of the Swedish Mammography Screening in Young Women Cohort study42 to
the epoch of digital mammography would be useful. The second question is whether or not alternative
or additional imaging modalities might be needed to improve the effectiveness of screening in this
age group because of the higher mammographic density in premenopausal women. There is already
ample evidence of increased detection from digital breast tomosynthesis, and from adding magnetic
resonance imaging or ultrasound to mammography.43,44 There is a need for further research to
determine to what extent this increased detection will be reflected in a greater effect on mortality
from breast cancer.
DISCUSSION AND IMPLICATIONS
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